Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
Julphar
US Army
Federal Trade Commission
McKinsey
Chinese Patent Office
Moodys
Baxter

Generated: May 24, 2018

DrugPatentWatch Database Preview

BENICAR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for BENICAR
Pharmacology for BENICAR
Synonyms for BENICAR
(5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-h
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-i midazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-iMidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl]-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazol-5-carboxylate;
(5-Methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate
144689-63-4
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
5-(1-Hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester
5-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-3-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-3H-IMIDAZOLE-4-CARBOXYLIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
689O634
6M97XTV3HD
A808260
AB0012006
AB01275443_02
AB01275443_03
AB01275443-01
AB1009487
AC-1601
AC1L2Y71
AK-72894
AKOS015894907
AKOS015914772
AN-1125
AOB3863
BC208264
BC209016
BCP9000555
BDBM50442892
Benevas
Benicar (TN)
BENICAR HCT
Benicar, Olmetec,Olmesartan
Berlin-Chemie Brand of Olmesartan Medoxomil
Bio-0071
BR-72894
BRD-K78485176-001-02-9
BSPBio_003491
C29H30N6O6
CAS-144689-63-4
CCG-221184
CCG-39596
CHEBI:31932
CHEBI:93384
CHEMBL1200692
CPD004727564
Cs 866
CS-0577
CS-866
CS-866DM
CS-866RN
CS866
D01204
D07UBG
DE-092
DR003267
DSSTox_CID_25924
DSSTox_GSID_45924
DSSTox_RID_81226
DTXSID9045924
EBD35964
Forest Brand of Olmesartan Medoxomil
FT-0601603
GTPL591
HE311789
HMS1922L15
HMS2089K18
HMS2093K16
HMS3651E13
HY-17005
I06-0025
I14-41691
J-501595
J10058
KBio2_002490
KBio2_005058
KBio2_007626
KBio3_002711
KBioGR_001040
KBioSS_002498
KS-00000IVQ
KS-1182
L001061
LS-181818
MCULE-2480015750
MFCD00944911
MLS006010109
NCGC00095136-01
NCGC00095136-02
NCGC00095136-03
NSC-758924
NSC758924
NU006784
O0510
Olmesartan (medoxomil)
Olmesartan medoximil
Olmesartan medoxomil
Olmesartan medoxomil (Benicar)
Olmesartan medoxomil (JAN/USAN)
Olmesartan medoxomil (JP17/USAN)
Olmesartan medoxomil [USAN:INN:BAN]
Olmesartan medoxomil for system suitability, European Pharmacopoeia (EP) Reference Standard
Olmesartan medoxomil tablets (JP17)
Olmesartan medoxomil, >=98% (HPLC)
Olmesartan medoxomil, European Pharmacopoeia (EP) Reference Standard
Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material
Olmesartan medoxomil, United States Pharmacopeia (USP) Reference Standard
Olmesartan medoxomil|4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-carboxylic acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Olmesartanmedoxomil
Olmetec
Olmetec (TN)
Olmetec; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1Htetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Olsertain
Olvance
Openvas
Pharmakon1600-01505205
RP17784
S-1787
s1604
SAM001246634
Sankyo Brand of Olmesartan Medoxomil
SBI-0206741.P001
SC-17112
SCHEMBL16403
SMR002203616
SPBio_000431
Spectrum_001944
SPECTRUM1505205
Spectrum2_000506
Spectrum3_001676
Spectrum4_000740
Spectrum5_001556
SR-05000001987
SR-05000001987-2
ST24031498
STL451024
Tox21_111445
UNII-6M97XTV3HD
UQGKUQLKSCSZGY-UHFFFAOYSA-N
votume
Z1550675457
ZINC4149248

US Patents and Regulatory Information for BENICAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-001 Apr 25, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-002 Jun 5, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-003 Apr 25, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-004 Apr 25, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for BENICAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-004 Apr 25, 2002 ➤ Sign Up ➤ Sign Up
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-001 Apr 25, 2002 ➤ Sign Up ➤ Sign Up
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-003 Apr 25, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BENICAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 20 mg/12.5 mg ➤ Subscribe 2007-05-11
➤ Subscribe Tablets 40 mg/12.5 mg and 40 mg/25 mL ➤ Subscribe 2007-02-15
➤ Subscribe Tablets 5 mg, 20 mg and 40 mg ➤ Subscribe 2006-04-25

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
Express Scripts
Dow
Chinese Patent Office
AstraZeneca
US Department of Justice
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.